<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:03:49 -0700</creation_date>
  <update_date>2013-05-27 11:41:06 -0600</update_date>
  <accession>HMDBP02242</accession>
  <secondary_accessions>
    <accession>7727</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Vitamin K1 2,3-epoxide reductase subunit 1</synonym>
  </synonyms>
  <gene_name>VKORC1</gene_name>
  <general_function>Involved in vitamin-K-epoxide reductase (warfarin-sensi</general_function>
  <specific_function>Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K.
</specific_function>
  <pathways>
    <pathway>
      <name>Vitamin K Metabolism</name>
      <smpdb_id>SMP00464</smpdb_id>
      <kegg_map_id></kegg_map_id>
    </pathway>
    <pathway>
      <name>Ubiquinone and other terpenoid-quinone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00130</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB03555</accession>
      <name>Vitamin K1</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02972</accession>
      <name>Vitamin K1 2,3-epoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04971</accession>
      <name>Glucosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01892</accession>
      <name>Menadione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01935</accession>
      <name>Warfarin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13593</accession>
      <name>1,4-Dithiothreitol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03156</accession>
      <name>2,3-Butanediol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14411</accession>
      <name>Dicumarol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14641</accession>
      <name>Phenindione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13880</accession>
      <name>S-6-Hydroxywarfarin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15081</accession>
      <name>Phenprocoumon</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15487</accession>
      <name>Acenocoumarol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04198</accession>
      <name>Reduced Vitamin K (phylloquinone)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59664</accession>
      <name>Oxidized dithiothreitol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60359</accession>
      <name>2,3-Epoxymenaquinone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB30017</accession>
      <name>Vitamin K2</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>vitamin-K-epoxide reductase (warfarin-sensitive) activity</description>
      <go_id>GO:0047057</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>drug metabolic process</description>
      <go_id>GO:0017144</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>peptidyl-glutamic acid carboxylation</description>
      <go_id>GO:0017187</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>post-translational protein modification</description>
      <go_id>GO:0043687</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>16</chromosome_location>
    <locus>16p11.2</locus>
    <gene_sequence>&gt;492 bp
ATGGGCAGCACCTGGGGGAGCCCTGGCTGGGTGCGGCTCGCTCTTTGCCTGACGGGCTTA
GTGCTCTCGCTCTACGCGCTGCACGTGAAGGCGGCGCGCGCCCGGGACCGGGATTACCGC
GCGCTCTGCGACGTGGGCACCGCCATCAGCTGTTCGCGCGTCTTCTCCTCCAGGTGGGGC
AGGGGTTTCGGGCTGGTGGAGCATGTGCTGGGACAGGACAGCATCCTCAATCAATCCAAC
AGCATATTCGGTTGCATCTTCTACACACTACAGCTATTGTTAGGTTGCCTGCGGACACGC
TGGGCCTCTGTCCTGATGCTGCTGAGCTCCCTGGTGTCTCTCGCTGGTTCTGTCTACCTG
GCCTGGATCCTGTTCTTCGTGCTCTATGATTTCTGCATTGTTTGTATCACCACCTATGCT
ATCAACGTGAGCCTGATGTGGCTCAGTTTCCGGAAGGTCCAAGAACCCCAGGGCAAGGCT
AAGAGGCACTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>163</residue_number>
    <molecular_weight>18234.3</molecular_weight>
    <theoretical_pi>9.361</theoretical_pi>
    <pfams>
      <pfam>
        <name>VKOR</name>
        <pfam_id>PF07884</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Vitamin K epoxide reductase complex subunit 1
MGSTWGSPGWVRLALCLTGLVLSLYALHVKAARARDRDYRALCDVGTAISCSRVFSSRWG
RGFGLVEHVLGQDSILNQSNSIFGCIFYTLQLLLGCLRTRWASVLMLLSSLVSLAGSVYL
AWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH</protein_sequence>
  </protein_properties>
  <genbank_protein_id>40217983</genbank_protein_id>
  <uniprot_id>Q9BQB6</uniprot_id>
  <uniprot_name>VKOR1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AY423044</genbank_gene_id>
  <genecard_id>VKORC1</genecard_id>
  <geneatlas_id>VKORC1</geneatlas_id>
  <hgnc_id>HGNC:23663</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41.</reference_text>
      <pubmed_id>14765194</pubmed_id>
    </reference>
    <reference>
      <reference_text>Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase.  Nature. 2004 Feb 5;427(6974):541-4.</reference_text>
      <pubmed_id>14765195</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.</reference_text>
      <pubmed_id>12975309</pubmed_id>
    </reference>
    <reference>
      <reference_text>Goodstadt L, Ponting CP: Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci. 2004 Jun;29(6):289-92.</reference_text>
      <pubmed_id>15276181</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tie JK, Nicchitta C, von Heijne G, Stafford DW: Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J Biol Chem. 2005 Apr 22;280(16):16410-6. Epub 2005 Feb 16.</reference_text>
      <pubmed_id>15716279</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J: Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost. 2005 Oct;94(4):780-6.</reference_text>
      <pubmed_id>16270630</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Menadione</name>
        <accession>HMDB01892</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Menadione</name>
        <accession>HMDB01892</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Menadione</name>
        <accession>HMDB01892</accession>
      </metabolite>
      <reference>
        <reference_text>Oldenburg J, Bevans CG, Muller CR, Watzka M: Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):347-53.</reference_text>
        <pubmed_id>16677080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Menadione</name>
        <accession>HMDB01892</accession>
      </metabolite>
      <reference>
        <reference_text>Stafford DW: The vitamin K cycle.  J Thromb Haemost. 2005 Aug;3(8):1873-8.</reference_text>
        <pubmed_id>16102054</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicumarol</name>
        <accession>HMDB14411</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicumarol</name>
        <accession>HMDB14411</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicumarol</name>
        <accession>HMDB14411</accession>
      </metabolite>
      <reference>
        <reference_text>Wallin R, Patrick SD, Ballard JO: Vitamin K antagonism of coumarin intoxication in the rat.  Thromb Haemost. 1986 Apr 30;55(2):235-9.</reference_text>
        <pubmed_id>2424118</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicumarol</name>
        <accession>HMDB14411</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindione</name>
        <accession>HMDB14641</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindione</name>
        <accession>HMDB14641</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindione</name>
        <accession>HMDB14641</accession>
      </metabolite>
      <reference>
        <reference_text>Mentre F, Pousset F, Comets E, Plaud B, Diquet B, Montalescot G, Ankri A, Mallet A, Lechat P: Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients.  Clin Pharmacol Ther. 1998 Jan;63(1):64-78.</reference_text>
        <pubmed_id>9465843</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindione</name>
        <accession>HMDB14641</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Gebauer M: Synthesis and structure-activity relationships of novel warfarin derivatives.  Bioorg Med Chem. 2007 Mar 15;15(6):2414-20. Epub 2007 Jan 17.</reference_text>
        <pubmed_id>17275317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G&gt;A) and CYP2C9 genotypes. Clin Chem. 2007 Jul;53(7):1199-205. Epub 2007 May 17.</reference_text>
        <pubmed_id>17510308</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11.</reference_text>
        <pubmed_id>17161452</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Osman A, Enstrom C, Lindahl TL: Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype.  Blood Coagul Fibrinolysis. 2007 Apr;18(3):293-6.</reference_text>
        <pubmed_id>17413769</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb;83(2):312-21. Epub 2007 Jul 25.</reference_text>
        <pubmed_id>17653141</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Schalekamp T, Brasse BP, Roijers JF, van Meegen E, van der Meer FJ, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007 Feb;81(2):185-93. Epub 2006 Dec 27.</reference_text>
        <pubmed_id>17192772</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR: A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005 Oct;2(10):e312. Epub 2005 Oct 11.</reference_text>
        <pubmed_id>16201835</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Thijssen HH, Baars LG: Microsomal warfarin binding and vitamin K 2,3-epoxide reductase.  Biochem Pharmacol. 1989 Apr 1;38(7):1115-20.</reference_text>
        <pubmed_id>2706010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Thijssen HH, Baars LG, Vervoort-Peters HT: Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity. Br J Pharmacol. 1988 Nov;95(3):675-82.</reference_text>
        <pubmed_id>3207986</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-40. Epub 2005 Mar 24.</reference_text>
        <pubmed_id>15790782</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Gonzalez-Conejero R, Corral J, Roldan V, Ferrer F, Sanchez-Serrano I, Sanchez-Blanco JJ, Marin F, Vicente V: The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost. 2007 Aug;5(8):1701-6. Epub 2007 May 21.</reference_text>
        <pubmed_id>17596133</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J: The c.-1639G &gt; A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006 Apr;133(2):183-7.</reference_text>
        <pubmed_id>16611310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH: A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol. 2006 Nov;62(5):617-20. Epub 2006 Jul 21.</reference_text>
        <pubmed_id>16869821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006 Jul;80(1):13-22.</reference_text>
        <pubmed_id>16815313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
